Arizona is currently home to 1658 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
NCT05664802
Recruiting
The goal of this study is to increase HIV and syphilis testing and linkage to care, increase condom use, and promote PrEP uptake among sexual minority men (SMM) and American Indian (AI) men in rural Oklahoma, a state that is an Ending the HIV Epidemic (EHE) priority state. The proposed supplement aims to: refine our preliminary intervention strategy in partnership with a Community Advisory Board (CAB) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the... Read More
Gender:
MALE
Ages:
Between 17 years and 29 years
Trial Updated:
03/19/2024
Locations: Northern Arizona University, Flagstaff, Arizona
Conditions: Human Immunodeficiency Virus (HIV)
Register for Updates
Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
NCT04905160
Recruiting
Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Multiple Locations, Phoenix, Arizona
Conditions: Heart Failure, ADHF, Acute MI
Register for Updates
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
NCT04844359
Recruiting
Up to 135 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/19/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Hypersensitivity Pneumonitis
Register for Updates
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
NCT04678193
Recruiting
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact seve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Multiple Locations, Phoenix, Arizona
Conditions: Covid19
Register for Updates
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
NCT04028492
Recruiting
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Peoria, Arizona
Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Goodyear, Arizona
Conditions: Neoplasms
Register for Updates
Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
NCT06321796
Recruiting
The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Pitt-Hopkins Syndrome (PTHS) and gastrointestinal problems (constipation, bloating, abdominal pain). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by 1 day of bowel cleanse using magnesium citrate, followed by 4 days of high dose MTP-101P with an antacid, followed by 12 weeks of a lower maintenance dose of MTP-101P with an antacid.
Gender:
ALL
Ages:
Between 5 years and 55 years
Trial Updated:
03/14/2024
Locations: Autism/Asperger's Research Group at Arizona State University, Tempe, Arizona
Conditions: Pitt Hopkins Syndrome
Register for Updates
Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned pembrolizumab monotherapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/12/2024
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Brain Tumor
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: Northern Arizona Healthcare, Cottonwood, Arizona
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Mayo Clinic, Phoenix, Arizona
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567
Recruiting
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Phoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
NCT04888104
Recruiting
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Adult Spinal Deformity, Scoliosis, Kyphosis
Register for Updates